Abstract GS4-10: Neratinib + fulvestrant + trastuzumab for hormone receptor-positive, HER2-mutant metastatic breast cancer and neratinib + trastuzumab for triple-negative disease: Latest updates from the SUMMIT trial
Year: 2022
Type: conference-abstract
Source: Cancer Research
Authors: Komal Jhaveri, Haeseong Park, James Waisman, Jonathan W Goldman, Angel Guerrero-Zotano, Valentina Boni, Barbara Haley, Ingrid A Mayer, Adam Brufsky, Eddy S Yang, José A García-Sáenz, François-Clement Bidard, John Crown, Bo Zhang, Aimee Frazier, Irmina Diala, Lisa D Eli, Brian Barnett, Hans Wildiers
Institutions: Memorial Sloan Kettering Cancer Center, Washington University in St. Louis, City Of Hope National Medical Center, University of California, Los Angeles, Fundación Instituto Valenciano de Oncología, Hospital Universitario HM Sanchinarro, The University of Texas Southwestern Medical Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Magee-Womens Hospital, University of Pittsburgh Medical Center, University of Alabama at Birmingham, Hospital Clínico San Carlos, Institut Curie, St. Vincent's University Hospital, Puma Biotechnology (United States), Universitair Ziekenhuis Leuven
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4221090583